258 related articles for article (PubMed ID: 38091917)
1. GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder.
Miller KN; Standeven L; Morrow AL; Payne JL; Epperson CN; Hantsoo L
Psychoneuroendocrinology; 2024 Feb; 160():106684. PubMed ID: 38091917
[TBL] [Abstract][Full Text] [Related]
2. Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder.
Hantsoo L; Grillon C; Sammel M; Johnson R; Marks J; Epperson CN
Psychopharmacology (Berl); 2021 Oct; 238(10):2985-2997. PubMed ID: 34292344
[TBL] [Abstract][Full Text] [Related]
3. Treatment of premenstrual dysphoric disorder with the GABA
Bixo M; Ekberg K; Poromaa IS; Hirschberg AL; Jonasson AF; Andréen L; Timby E; Wulff M; Ehrenborg A; Bäckström T
Psychoneuroendocrinology; 2017 Jun; 80():46-55. PubMed ID: 28319848
[TBL] [Abstract][Full Text] [Related]
4. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.
Martinez PE; Rubinow DR; Nieman LK; Koziol DE; Morrow AL; Schiller CE; Cintron D; Thompson KD; Khine KK; Schmidt PJ
Neuropsychopharmacology; 2016 Mar; 41(4):1093-102. PubMed ID: 26272051
[TBL] [Abstract][Full Text] [Related]
5. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study.
Epperson CN; Haga K; Mason GF; Sellers E; Gueorguieva R; Zhang W; Weiss E; Rothman DL; Krystal JH
Arch Gen Psychiatry; 2002 Sep; 59(9):851-8. PubMed ID: 12215085
[TBL] [Abstract][Full Text] [Related]
6. Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder.
Bixo M; Johansson M; Timby E; Michalski L; Bäckström T
J Neuroendocrinol; 2018 Feb; 30(2):. PubMed ID: 29072794
[TBL] [Abstract][Full Text] [Related]
7. GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder.
Sikes-Keilp C; Rubinow DR
CNS Drugs; 2023 Aug; 37(8):679-693. PubMed ID: 37542704
[TBL] [Abstract][Full Text] [Related]
8. Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study.
Timby E; Bäckström T; Nyberg S; Stenlund H; Wihlbäck AN; Bixo M
Psychopharmacology (Berl); 2016 Jun; 233(11):2109-2117. PubMed ID: 26960697
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum.
Porcu P; O'Buckley TK; Alward SE; Marx CE; Shampine LJ; Girdler SS; Morrow AL
Steroids; 2009; 74(4-5):463-73. PubMed ID: 19171160
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of ethanol on serum GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in mice, rats, cynomolgus monkeys, and humans.
Porcu P; O'Buckley TK; Alward SE; Song SC; Grant KA; de Wit H; Leslie Morrow A
Alcohol Clin Exp Res; 2010 Mar; 34(3):432-42. PubMed ID: 20028362
[TBL] [Abstract][Full Text] [Related]
11. Emotion-induced brain activation across the menstrual cycle in individuals with premenstrual dysphoric disorder and associations to serum levels of progesterone-derived neurosteroids.
Stiernman L; Dubol M; Comasco E; Sundström-Poromaa I; Boraxbekk CJ; Johansson M; Bixo M
Transl Psychiatry; 2023 Apr; 13(1):124. PubMed ID: 37055419
[TBL] [Abstract][Full Text] [Related]
12. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle.
Hantsoo L; Epperson CN
Neurobiol Stress; 2020 May; 12():100213. PubMed ID: 32435664
[TBL] [Abstract][Full Text] [Related]
13. Moderate doses of ethanol fail to increase plasma levels of neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one-like immunoreactivity in healthy men and women.
Holdstock L; Penland SN; Morrow AL; de Wit H
Psychopharmacology (Berl); 2006 Jun; 186(3):442-50. PubMed ID: 16240164
[TBL] [Abstract][Full Text] [Related]
14. Effects of estrogen and progesterone on neuroactive steroids and cytokines in patients with suicidality.
Barone JC; Wenzel E; Alluri V; Moriarity D; Pinna G; Walsh E; Rubinow DR; Morrow AL; Eisenlohr-Moul TA
Psychoneuroendocrinology; 2023 Nov; 157():106359. PubMed ID: 37611527
[TBL] [Abstract][Full Text] [Related]
15. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.
Yonkers KA; Kornstein SG; Gueorguieva R; Merry B; Van Steenburgh K; Altemus M
JAMA Psychiatry; 2015 Oct; 72(10):1037-44. PubMed ID: 26351969
[TBL] [Abstract][Full Text] [Related]
16. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder.
Girdler SS; Straneva PA; Light KC; Pedersen CA; Morrow AL
Biol Psychiatry; 2001 May; 49(9):788-97. PubMed ID: 11331087
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder.
Bäckström T; Ekberg K; Hirschberg AL; Bixo M; Epperson CN; Briggs P; Panay N; O'Brien S
Psychoneuroendocrinology; 2021 Nov; 133():105426. PubMed ID: 34597899
[TBL] [Abstract][Full Text] [Related]
18. ShuYu capsule alleviates emotional and physical symptoms of premenstrual dysphoric disorder: Impact on ALLO decline and GABA
Geng X; Wang X; Liu K; Xing Y; Xu J; Li Z; Zhang H; Hu M; Gao P; Chen D; Liu W; Li K; Wei S
Phytomedicine; 2024 Jul; 130():155549. PubMed ID: 38810551
[TBL] [Abstract][Full Text] [Related]
19. Allopregnanolone and mood disorders.
Bäckström T; Bixo M; Johansson M; Nyberg S; Ossewaarde L; Ragagnin G; Savic I; Strömberg J; Timby E; van Broekhoven F; van Wingen G
Prog Neurobiol; 2014 Feb; 113():88-94. PubMed ID: 23978486
[TBL] [Abstract][Full Text] [Related]
20. Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA.
Hantsoo L; Payne JL
Neurosci Biobehav Rev; 2023 Jun; 149():105168. PubMed ID: 37059403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
